PT714444E - Atenuacao de um epitopo imunodominante de um antigenio para utilizacao em vacinas e imunoterapias para plantas, animais e homens - Google Patents

Atenuacao de um epitopo imunodominante de um antigenio para utilizacao em vacinas e imunoterapias para plantas, animais e homens

Info

Publication number
PT714444E
PT714444E PT94925937T PT94925937T PT714444E PT 714444 E PT714444 E PT 714444E PT 94925937 T PT94925937 T PT 94925937T PT 94925937 T PT94925937 T PT 94925937T PT 714444 E PT714444 E PT 714444E
Authority
PT
Portugal
Prior art keywords
immunodominant
antigen
epitopo
atenuation
immunotherapies
Prior art date
Application number
PT94925937T
Other languages
English (en)
Inventor
Robert R Garrity
Peter L Nara
Jaap Goudsmit
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of PT714444E publication Critical patent/PT714444E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT94925937T 1993-08-20 1994-08-19 Atenuacao de um epitopo imunodominante de um antigenio para utilizacao em vacinas e imunoterapias para plantas, animais e homens PT714444E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/109,934 US5585250A (en) 1993-08-20 1993-08-20 Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies

Publications (1)

Publication Number Publication Date
PT714444E true PT714444E (pt) 2002-07-31

Family

ID=22330363

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94925937T PT714444E (pt) 1993-08-20 1994-08-19 Atenuacao de um epitopo imunodominante de um antigenio para utilizacao em vacinas e imunoterapias para plantas, animais e homens

Country Status (11)

Country Link
US (2) US5585250A (pt)
EP (1) EP0714444B1 (pt)
JP (2) JP3851938B2 (pt)
AT (1) ATE211767T1 (pt)
AU (1) AU700786B2 (pt)
CA (2) CA2169764C (pt)
DE (1) DE69429625T2 (pt)
DK (1) DK0714444T3 (pt)
ES (1) ES2170771T3 (pt)
PT (1) PT714444E (pt)
WO (1) WO1995006124A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
EP0862584B1 (en) * 1995-11-03 2004-12-22 The Binding Site Limited Production of antibodies
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6936249B1 (en) * 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US20020182180A1 (en) * 1998-05-29 2002-12-05 Yutaro Kaneko Method for inducing immunity to viruses
ATE365210T1 (de) * 1998-10-30 2007-07-15 Novozymes As Glykosylierte proteine mit reduzierter allergenität
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
US7078043B2 (en) 1999-04-20 2006-07-18 Medical Research Council Malaria vaccine
EP1237971B1 (de) 1999-11-29 2010-08-04 Henkel AG & Co. KGaA Haftungsverstärker für monomerfreie reaktive polyurethane
DE10055786A1 (de) * 2000-11-10 2002-05-29 Henkel Kgaa Haftungsverstärker für monomerfreie reaktive Polyurethane
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
AU2003300870A1 (en) * 2002-12-11 2004-06-30 The Scripps Research Institute Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same
US7514539B2 (en) * 2004-04-26 2009-04-07 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
US7790405B2 (en) * 2004-04-26 2010-09-07 Centocor, Inc. Solution phase biopanning method using engineered decoy proteins
CA2573313A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Antibodies against cancer produced using masked cancer cells as immunogen
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006105993A2 (en) * 2005-04-05 2006-10-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for shielding functional sites or epitopes on proteins
US20090162383A1 (en) * 2006-12-26 2009-06-25 Padlan Eduardo A Method for designing vaccines against constantly mutating pathogens
WO2009105729A2 (en) * 2008-02-21 2009-08-27 Biological Mimetics, Inc. Immunogenic influenza composition
US9782472B2 (en) 2008-10-04 2017-10-10 The Regents Of The University Of California Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
WO2010064204A2 (en) * 2008-12-02 2010-06-10 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Modified protozoan expressing at least two variable surface proteins (vsp), a vaccine comprising it and procedures, uses, and methods thereof
WO2010077643A1 (en) * 2008-12-08 2010-07-08 Tegopharm Corporation Masking ligands for reversible inhibition of multivalent compounds
WO2011028963A2 (en) * 2009-09-03 2011-03-10 Biological Mimetics, Inc. Immunogenic hiv composition
CN102985107A (zh) 2010-01-24 2013-03-20 生物模仿公司 免疫性流感成分
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
WO2012082634A1 (en) 2010-12-13 2012-06-21 University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP3269728B1 (en) 2011-10-20 2020-12-16 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
NZ704188A (en) 2012-07-17 2016-04-29 Merial Inc Attenuated swine influenza vaccines and methods of making and use thereof
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3145546B1 (en) * 2014-02-19 2020-12-09 Emergent BioSolutions Canada Inc. Marburg monoclonal antibodies
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CN107074965B (zh) 2014-06-26 2021-08-03 扬森疫苗与预防公司 特异性结合微管相关蛋白tau的抗体和抗原结合片段
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
AU2019247034A1 (en) * 2018-04-03 2020-10-22 Sanofi Antigenic respiratory syncytial virus polypeptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies

Also Published As

Publication number Publication date
EP0714444B1 (en) 2002-01-09
JP2006104216A (ja) 2006-04-20
CA2169764A1 (en) 1995-03-02
ES2170771T3 (es) 2002-08-16
WO1995006124A1 (en) 1995-03-02
US5853724A (en) 1998-12-29
DE69429625T2 (de) 2002-09-12
EP0714444A1 (en) 1996-06-05
DE69429625D1 (de) 2002-02-14
ATE211767T1 (de) 2002-01-15
CA2169764C (en) 2008-04-15
AU700786B2 (en) 1999-01-14
DK0714444T3 (da) 2002-04-29
US5585250A (en) 1996-12-17
AU7569294A (en) 1995-03-21
CA2623540A1 (en) 1995-03-02
JP3851938B2 (ja) 2006-11-29
JPH09501933A (ja) 1997-02-25

Similar Documents

Publication Publication Date Title
PT714444E (pt) Atenuacao de um epitopo imunodominante de um antigenio para utilizacao em vacinas e imunoterapias para plantas, animais e homens
DE69637481D1 (de) Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
ES2184769T3 (es) Metodos y composiciones para microencapsulacion de antigenos para utilizar como vacunas.
AP2003002937A0 (en) One dose vaccination with mycoplasma hyopneumoniae
NL940017I1 (nl) Vaccin-preparaat
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
GT200300180A (es) Vacunas para enfermedades reproductoras del ganado
ATE255419T1 (de) Für den vogelembryo geeignete multivalente impfstoffe
BG95337A (bg) Ваксиниране и методи срещу заболявания,резултат от патогенни отговори на т-клетъчно специфични популации
EA199800946A1 (ru) Концентрированный препарат антител
SE7512828L (sv) Calicivirusvaccin
HUP9701586A2 (hu) Javított inaktivált vakcinák
RU2020109137A (ru) Вакцина для защиты от streptococcus suis
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
ES2166763T3 (es) Inmunizacion parenteral contra rotavirus.
ES2057008T3 (es) Medicamento.
ES2158857T3 (es) Vacunas a base de estreptoquinasa.
FR2385401A1 (fr) Vaccin a virus respiratoire syncytial
ES2102836T3 (es) El empleo de vacunas antihelminticas en el control de la enfermedad parasitaria asociada con la perdida de la inmunidad natural.
PT1194450E (pt) Vacina inactivada contra a calicivirose felina
DE69833568D1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
Mudema Studies on Immunological Effect and Immunological Mechanism Avian Encephalomyelitis Oil Emulsion Inactivated Vaccine
DE69123252D1 (de) Kreuzreaktive immunisierung gegen influenza